Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Mantle cell lymphoma, drawn from the whole corpus: 41 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
TP53-mutant and blastoid MCL fail chemo-immunotherapy; need CAR-T or bispecific-based first-line trials.
MRD-guided treatment duration.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Whether CAR-T should precede pirtobrutinib or follow it.
Cost and access of indefinite BTK-inhibitor therapy.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 20 changes by month →When this page itself was last checked or edited.
Relapsed/refractory mantle cell lymphoma after ≥2 lines including a BTK inhibitor (accelerated)
A milestone in how this cancer is treated.
Median progression-free survival 31.
Three-year failure-free survival 88 percent with ibrutinib added to induction, transplant and maintenance against 72 percent with standard induction and transplant (hazard ratio 0.
Ibrutinib replaces transplant in fit patients; acalabrutinib + BR improves PFS first line in older patients.